Adverse CNS-effects of beta-adrenoceptor blockers

Pharmacopsychiatry

Volumn 29, Issue 6, 1996, Pages 201-211

  Gleiter, C H ^a   Deckert, J ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; METOPROLOL; PINDOLOL; PROPRANOLOL;

ADVERSE DRUG REACTION; ANXIETY; CENTRAL NERVOUS SYSTEM; DEPRESSION; DRUG MECHANISM; HUMAN; MIGRAINE; NEUROTOXICITY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; TREMOR;

EID: 0029805175     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979572     Document Type: Review

References (142)

1. Aarons, R. D., A. S. Nies, J. Gal et al.: Elevation of beta-adrenergic receptor density in human lymphocytes after propranolol administration. J. Clin. Invest. 65 (1980) 949-957
2. Abramsky, O., A. Carmon, S. Lavy: Combined treatment of Parkinsonian tremor with propranolol and levodopa. J. Neural. Sci. 14 (1971) 491-494
3. Adler, L., B. Angrist, E. Pepselow et al.: A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. Br. J. Psychiatry 149 (1986) 42-45
4. Al-Quassab, H., L. A. Cleeves, P. L. Francis et al.: Is there a central nervous withdrawal syndrome associated with discontinuing long-term treatment with propranolol. Human Toxicol. 7 (1989) 249-254
5. Andersson, K. E., E. Vinge: Beta-adrenoceptor blockers and calcium antagonists in the prophylaxis and treatment of migraine. Drugs 39 (1990) 355-373
6. Annane, D.: Medication beta-adrenergique de la commande central de la ventilation: mythe ou realite? J. Tox. Clin. Exp. 11 (1991) 325-336
7. Anonymus: A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 247 (1982) 1707-1714
8. Arensberg, D., N. K. Wenger: A probable result of propranolol therapy. Int. J. Addict 14 (1979) 785-787
9. Arnold, J. M. O., G. D. Johnston, D. W. G. Harron et al.: The effect of ICI 118-551 on isoprenaline-induced betaadrenoceptor responses in man. Br. J. Clin. Pharmac. 15 (1982) 133-134P
10. Atsmon, A., I. Blum: Propranolol and psychoses - initial discovery. In: Amacher, R. (ed.): Propranolol and schizophrenia. Liss, New York (1978) pp 5-38
11. Avorn, J., D. Everitt, S. Weiss: Increased antidepressant use in patients described beta-blockers. JAMA 255 (1986) 357-360
12. Baumel, B.: Migraine: a pharmacologic review with newer options and delivery modalities. Neurology 44 (Suppl. 3) (1994) S13-17
13. Behan, P. O., K. Connelly: Prophylaxis of migraine: a comparison between naproxen sodium and pizotifen. Headache 26 (1986) 237-239
14. Bekes, M., L. Matos, J. Rausch et al.: Treatment of migraine with propranolol. Lancet II (1980) 980
15. Borchard, U.: Beta-Rezeptorenblocker. In: Riederer, P., G. Laux, W. Pöldinger (eds.): Neuropsychopharmaka. Vol 6. Springer, Wien, (1992) pp 99-110
16. Bougeois, J. A.: Depression and topical ophthalmic beta adrenergic blockade. J. Am. Optom. Assoc. 62 (1991) 403-406
17. Bright, R. A., D. E. Everitt: Beta-blockers and depression. Evidence against an association. JAMA 267 (1992) 1783-1787
18. Burton, K.: The treatment of tremor. Med. J. Australia 147 (1987) 503-506
19. Büttner, U., E. Scholz: Tremor. In: Brandt, T., J. Dichgans, H. C. Diener (eds.): Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart (1993) pp 253-259
20. Calzetti, S., L. J. Findley, M. A. Gresty et al.: Metoprolol and propranolol in essential tremor: a double-blind controlled study. J. Neurol. Neurosurg. Psychiatry 45 (1981) 893-897
21. Calzetti, S., L. J. Findley, M. A. Gresty et al.: Effect of a single oral dose of propranolol on essential tremor: a double-blind controlled study. Ann. Neurol. 13 (1983a) 165-171
22. Calzetti, S., L. J. Findley, E. Perucca et al.: The response of essential tremor to propranolol - evaluation of clinical variables governing its efficacy on prolonged administration. J. Neurol. Neurosurg. Psychiatry 45 (1983b) 393-398
23. Carney, R. M., M. W. Rich, A. teVelde et al.: Prevalence of major depressive disorder in patients receiving betablocker therapy versus other medications. Am. J. Med. 83 (1987) 223-226
24. Cleeves, L., L. J. Findley: Propranolol and Propranolol-LA in essential tremor: a double-blind comparative study. J. Neurol. Neurosurg. Psychiatry 51 (1988) 379-384
25. Cleeves, L., L. J. Findley: Tremors. Med. Clin. North America 73 (1989) 1307-1319
26. Clement, K., C. Vaisse, B. St. J. Manning et al.: Genetic variation in the β-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N. Engl. J. Med. 333 (1995) 352-354
27. Collins, S., J. Ostrowski: Cloning and sequence analysis of the human beta-1 adrenergic 5′-flanking promotor region. Biochem. Biophys. Acta 1172 (1993) 171-174
28. Coplan, J. D., L. Tiffon, J. M. Gorman: Therapeutic strategies for the patient with treatment-resistant anxiety. J. Clin. Psychiatry 54 (Suppl. 5) (1993) 69-74
29. Costain, D. W., A. R. Green: Beta-adrenoceptpor antagonists inhibit the behavioral responses of rats to increased brain 5-hydroxytryptamine. Br. J. Pharmacol. 164 (1978) 193-200
30. Cove-Smith, J. K., C. A. Kirk: CNS-related side-effects with metoprolol and atenolol. Eur. J. Clin. Pharmacol. 28 (Suppl.) (1985) 69-72
31. Cremona-Barbacia, A.: Propranolol and depression. Lancet I (1993) 185
32. Cruickshank, J. M.: The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am. Heart J. 100 (1980) 160-178
33. Cummings, J., N. A. Hobbon, L. Obler et al.: Nonaphasic misnaming and other neurobehavioral features of an unusual toxic encephalopathy: case study. Cortex 16 (1980) 315-323
34. Currie, D., R. V. Lewis, D. G. McDevitt et al.: Central effects of beta-adrenoceptor antagonists. I. Performance and subjective assessments of mood. Br. J. Clin. Pharmac. 26 (1988) 121-128
35. Deckert, J., C. H. Gleiter, H. Przuntek: Organic anxiety syndrome after withdrawal of atenolol. Am. J. Psychiatry 151 (1994) 1840
36. Diamond, S., L. Kudrow, J. Stevens et al.: Long-term study of propranolol in the treatment of migraine. Headache 22 (1982) 268-271
37. Dietrichson, P., E. Espen: Effects of timolol and atenolol on benign essential tremor: Placebo-controlled studies based on quantitative tremor recording. J. Neurol. Neurosurg. Psychiatry 44 (1981) 677-683
38. Dietrichson, P., E. Espen: Primidone and propranolol in essential tremor: a study based on quantitative tremor recording and plasma anticonvulsant levels. Acta Neurol. Scand. 75 (1987) 332-340
39. Drew, P. J. T., J. N. Barnes, S. J. W. Evans: The effect of acute β-adrenoceptor blockade on examination performance. Br. J. clin. Pharmac. 19 (1985) 783-786
40. Duch, S., C. Duch, L. Pasto et al.: Changes in depressive status associated with topical beta-blockers. Int. Ophthalmol. 6 (1992) 331-335
41. Duman, R. S., E. J. Nestler: Signal transduction pathways for catecholamin receptors. Bloom, F. E., D. J. Kupfer (eds.): Psychopharmacology. The fourth generation of progress. Raven Press, New York (1995) pp 303-320
42. Duncan, G. E., K. Y. Little, P. A. Koplas et al.: Beta-adrenergic receptor distribution in human and rat hippocampal formation: marked species differences. Brain Res. 561 (1991) 84-92
43. Emorine, L., N. Blin, A. D. Strosberg: The human β3-adrenoceptor: the search for a physiological function. Trends Pharmacol. Sci. 15 (1994) 3-7
44. Erdmann, J., D. Shimron-Abarbanell, S. Cichon et al.: Systematic screening for mutations in the promoter and the coding region of the 5-HT 1A gene. Am. J. Med. Genet. 60 (1995) 393-399
45. Findley L. J., W. C. Koller: Essential tremor: a review. Neurology 37 (1987) 1194-1197
46. Fleming, P. D., D. A. Drachman: Propranolol, hallucinations, and sleep disturbance. Am. J. Psychiatry 138 (1982) 850-851
47. Fleminger, R.: Visual hallucinations and illusions with propranolol. Br. Med. J. I (1978) 182
48. Fraunfelder, F. T.: Ocular beta-blockers and systemic effects. Arch. Int. Med. 146 (1986) 1073-1074
49. Fraser, H. S., A. C. Carr: Propranolol psychosis. Brit. J. Psychiatry 129 (1976) 508-512
50. Frielle, T., K. W. Daniel, M. G., Caron et al.: Structural basis of beta-adrenergic receptor subtype specificity studied with chimeric beta 1/beta2-adrenergic receptors. PNAS USA 85 (1988) 9494-9498
51. Frishman, W.: Beta-adrenergic blocker withdrawal. Am. J. Cardiol. 59 (1987) 26F-32F
52. Frommberger, U., J. Angenendt, M. Berger: Die Behandlung von Panikstörungen und Agoraphobien. Psychotherapie, Psychopharmakotherapie und deren Kombination. Nervenarzt 66 (1995) 173-186
53. Gaby, N. S., D. S. Lefkowitz, J. R. Israel: Treatment of lithium tremor with metoprolol. Am. J. Psychiatry 140 (1983) 593-595
54. Gastpar, M., J. Rimpel: Beta-Rezeptorenblocker-Klinik. In: Riederer, P., G. Laux, W. Pöldinger (eds.): Neuropsychopharmaka Vol. 6, Springer, Wien (1993) pp 111-124
55. Geffner, D. L., J. M. Hershman: β-adrenergic blockade for the treatment of hyperthyroidism. Am. J. Med. 93 (1992) 61-68
56. Gershon, E. S., R. E. Goldstein, A. J. Moss et al.: Psychosis with ordinary doses of propranolol. Ann. Int. Med. 90 (1979) 938-939
57. Glaubiger, G., R. J. Lefkowitz: Elevated beta-adrenergic receptor number after chronic propranolol treatment. Biochem. Biophys. Res. Commun. 78 (1977) 720
58. Gleiter, C. H., D. J. Nutt: Chronic electroconvulsive shock and neurotransmitter receptors - an update. Life Sci. 44 (1989) 985-1006
59. Glennon, R. A., M. Dukat: Serotonin receptor subtypes. In: Bloom, F. E., D. J. Kupfer (eds.): Psychopharmacology. The fourth generation of progress. Raven Press, New York (1995) pp 415-429
60. Golden, R. N., J. Hoffmann, D. Falk et al: Psychoses associated with propranolol withdrawal. Biol. Psychiatry 25 (1989) 351-354
61. Granville-Grossman, K. L., P. Turner: The effect of propranolol on anxiety. Lancet I (1966) 788-790
62. Green, S. A., G. Cole, M. Jacinto et al.: A polymorphism of the human β2-adrenergic receptor within the fourth transmembrane domaine alters ligand binding and functional properties of the receptor. J. Biol. Chem. 268 (1993) 23116-23121
63. Greenblatt, D. J., J. Koch-Weser: Adverse reactions to beta-adrenergic blocking drugs: a report from the Boston collaborative drug surveillance program. Drugs 7 (1974) 118-129
64. Guan, X. M., S. J. Peroutka: Basic mechanisms of action of drugs used in the treatment of essential tremor. Clin. Neuropharmacol. 13 (1990) 210-223
65. Hall, I. P., A. Wheatley, P. Wilding et al.: Association of Glu27 β2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 345 (1995) 1213-1214
66. Henry, M., A. Morera, A. S. Frugoni et al.: Psychopathological profile in chronic bronchial asthma. Europ. Psychiatry 8 (1993) 209-212
67. Helson, L., L. Duque: Acute brain syndrome after propranolol. Lancet I (1978) 98
68. Hinshelwood, R. D.: Hallucinations and propranolol. Br. Med. J. II (1969) 445
69. James, I. M.: Practical aspects of the use of beta-blockers in anxiety states: situational anxiety. Postgrad. Med. J. 60 (Suppl. 2) (1984) pp 19-25
70. James, I., I. Savage: Beneficial effects of nadolol on anxiety-induced disturbances of performance in musicians: A comparison with diazepam and placebo. Am. Heart J. 1018 (1984) 1150-1155
71. Johansson, V., L. R. Nilsson, T. Widelius et al.: Atenolol in migraine prophylaxis: a double-blind cross-over multicenter study. Headache 27 (1987) 372-374
72. Johnson, G., B. Singh, M. Leeman: Controlled evaluation of the beta-adrenergic blocking drug oxprenolol in anxiety. Med. J. Aust. 1 (1976) 909-912
73. Jouvent, R., P. Baruch, P. Simon: Manic episode after propranolol withdrawal. Am. J. Psychiatry 143 (1986) 1633
74. Kathol, R. C., R. Noyes, D. J. Slymen et al.: Propranolol in chronic anxiety disorders: a controlled study. Arch. Gen. Psychiatry 37 (1980) 1361-1365
75. Koehler, K., W. Guth: Schizophrenie-ähnliche Psychose nach Einnahme von Propranolol. Münch. Med. Wschr. 119 (1977) 443-444
76. Koller, W. C.: Nadolol in essential tremor. Neurology 33 (1983) 1067-1077
77. Koller, W., B. Vetere-Overfield: Acute and chronic effects of propranolol and primidone in essential tremor. Neurology 39 (1989) 1587-1588
78. Kraus, M. L., L. D. Gottlieb, R. I. Horwitz et al.: Randomized clinical trial of atenolol in patients with alcohol withdrawal. N. Engl. J. Med. 313 (1985) 905-909
79. Kurland, M. L.: Organic brain syndrome with propranolol. N. Engl. J. Med. 300 (1979) 366
80. Kurtz, S., I. Ashkenazi, S. Melamed: Major depressive episode secondary to antiglaucoma drugs. Am. J. Psychiatry 150 (1993) 524 -525
81. Lader, M.: β-adrenoceptor antagonists in neuropsychiatry: an update. J. Clin. Psychiatry 49 (1988) 213-223
82. Langemeijer, J. J. M., D. J. De Wildt, C. de Groot et al.: Intoxication with beta-sympatholytics. Neth. J. Med. 40 (1992) 308-315
83. Lapierre, Y. D.: Control of lithium tremor with propranolol. Can. Med. Ass. J. 114 (1976) 619-624
84. Lasek, R., B. Mathias: Unerwünschte zentralnervöse Wirkungen von beta-Rezeptorenblockern. Tägl. Praxis 33 (1992) 141-146
85. Lecrubier, Y., A. J. Puech, H. Frances et al.: Beta-adrenergic stimulation and antidepressant activity. Acta. Psychiat. Scand. 63 (1981) 173-178
86. Leigh, P. N., D. Jefferson, A. Twomey et al.: Beta-adrenoceptor mechanisms in essential tremor: a double-blind placebo controlled trial of metoprolol, sotalol and atenolol. J. Neurol. Neurosurg. Psychiatry 46 (1983) 710-715
87. Lücking, C. H., W. Oestreich, R. Schmidt et al.: Flunarizine vs propranolol in the prophylaxis of migraine: two double-blind comparative studies in more than 400 patients. Cephalgia 8 (Suppl. 8) (1988) 21-26
88. Lynch, M. G., J. T. Whitson, R. H. Brown et al.: Tropical beta-blocker therapy and central nervous system side effects. Arch. Ophthalmol. 106 (1988) 908-911
89. Main, B. G., H. Tucker: Recent advances in β-adrenergic blocking agents. In: Ellis, G. P., G. B. West (eds.): Progress in medicinal chemistry. Vol. 22. Elsevier, Amsterdam (1985) pp 122-164
90. Marsden, C. W., J. C. Meadows: The effect of adrenaline on the contraction of human muscle. J. Physiol. 207 (1970) 429-448
91. McAinsh, J., J. M. Cruickshank: Beta-blockers and central nervous system side effects. Pharmac. Ther. 46 (1992) 163-197
92. McGanan, D. J., A. Wojslaw, V. Prasad et al.: Propranolol-induced psychosis. Drug Intell. Clin. Pharm. 18 (1984) 601-603
93. McMillin, W. P.: Oxprenolol in the treatment of anxiety due to environmental stress. Am. J. Psychiatry 132 (1975) 965-968
94. McTavish, D., D. Campoli-Richards, E. M. Sorkin: Carvedilol. A review on its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 45 (1993) 232-258
95. Medical Research Council Working Party on Mild to Moderate Hypertension: Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet II (1981) 539-543
96. Moskowitz, M. A., R. Macfarlane: Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc. Brain Metabol. Rev. 5 (1993) 159-177
97. Munjack D. J., R. Rebal, R. Shaner et al.: Imipramine versus propranolol for the treatment of panic attacks: a pilot study. Compr. Psychiatry 26 (1985) 80-89
98. Munjack, D. J., B. Crocker, D. Cabe et al.: Alprazolam, propranolol and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J. Clin. Psychopharmacol. 9 (1989) 22-27
99. Murray, T. J.: Long-term therapy of essential tremor with propranolol. Can. Med. Assoc. J. 115 (1976) 892-894
100. Nicholson, N., N. A. Wright, M. B. Zeitlein et al.: Central effects of β-adrenoceptor antagonists II - electroencephalogram and body sway. Br. J. Clin. Pharmac. 26 (1988) 129-141
101. Norwegian Multicenter Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N. Engl. J. Med. 304 (1981) 801-807
102. Orlando, R. G.: Clinical depression associated with betaxolol. Am. J. Ophtalmol. 102 (1986) 275
103. Owen, D. A. L., C. D. Marsden: Effect of adrenergic blockade on Parkinsonian tremor. Lancet II (1965) 1259-1262
104. Palm, D., D. Hellenbrecht, K. Quiring: Pharmakologie adrenerger und noradrenerger Systeme. In: Forth, W., D. Henschler, W. Rummel, K. Starke (eds.): Pharmakologie und Toxikologie. BI Wissenschaftsverlag, Mannheim (1992) pp 148-199
105. Patterson, J. F.: Propranolol-induced mania. South Med. J. 77 (1984) 1603
106. Patterson, J. F.: Psychosis following discontinuation of a long-acting propranolol preparation. J. Clin. Psychopharmacol. 5 (1985) 125-126
107. Paykel, E. S., R. Fleminger, J. P. Watson: Psychiatric side effects of antihypertensive drugs other than reserpine. J. Clin. Psychopharmacol. 2 (1982) 14-39
108. Pazos, A., A. Probst, A. Palacios: β-Adrenoceptor subtypes in the human brain: autoradiographic localization. Brain Res. 358 (1985) 324-328
109. Pazos, A., A. Probst, J. M. Palacios: Serotonin receptors in the human brain - III. Autoradiographic mapping of serotonin-1 receptors. Neuroscience 21 (1987) 97-122
110. Peroutka, S. J.: Antimigraine drug interactions with serotonin receptor subtypes in human brain. Ann. Neurol. 23 (1988) 500-504
111. Peroutka, S. J.: The pharmacology of current anti-migraine drugs. Headache 30 (Suppl. 1) (1990) 5-11
112. Petrie, W. M., R. J. Maffucci, R. L. Woosley: Propranolol and depression. Am. J. Psychiatry 139 (1982) 92-94
113. Pfaffenrath, V., H. C. Diener, H. Isler et al.: Efficacy and tolerability of amitriptylinoxide in chronic tension-type headache: a multicentre controlled study. Cephalgia 14 (1994) 149-155
114. Reznikoff, G. A., S. Manaker, C. H. Rhodes et al.: Localization and quantification of beta-adrenergic receptors in human brain. Neurology 36 (1986) 1067-1073
115. Rodriguez, M., C. Carillon, A. Coquerel et al.: Evidence for the presence of beta 3-adrenergic receptor mRNA in the human brain. Mol. Brain Res. 29 (1995) 369-375
116. Rosen, J. A.: Observations on the efficacy of propranolol for the prophylaxis of migraine. Ann. Neurol. 13 (1983) 92-93
117. Rosenthal, S., E. Ellison: Propranolol withdrawal in psychosis. Am. J. Psychiatry 147 (1990) 534
118. Saul, P., B. P. Jones, K. G. Edwards et al.: Randomized comparison of atenolol and placebo in the treatment of anxiety: a double-blind study. Eur. J. Clin. Pharmacol. 28 (Suppl.) (1985) 109-110
119. Schleifer, S. J., W. R. Slater, M. M. Macari-Hinson et al: Digitalis and β-blocking agents: effects on depression following myocardial infarction. Am. Heart J 121 (1991) 1397-1402
120. Schweizer, R., W. T. Roth, T. Elbert: Effects of two β-blockers on stress during mental arithmetic. Psychopharmacology 105 (1991) 573-577
121. Sevitt, I.: The effect of adrenergic beta-receptor blocking drugs on tremor. Practitioner 207 (1971) 677-678
122. Shih, J. C., K. J. S. Chen, T. K. Gallaher: Molecular biology of serotonin receptors. In: Bloom, F. E., D. J. Kupfer (eds.): Psychopharmacology. The fourth generation of progress. Raven Press, New York (1995) pp 407-414
123. Silberstein, S. D., R. B. Lipton: Overview of diagnosis and treatment of migraine. Neurology 44 (10 Suppl. 7) (1994) S6-S16
124. Sorgi, P., J. Ratey, D. Knoedler et al.: Depression during treatment with beta-blockers: Results from a doubleblind placebo-controlled study. J. Neuropsychiatry Clin. Neurosci. 4 (1992) 187-189
125. Soyka, D., H. C. Diener, V. Pfaffenrath et al.: Therapie und Prophylaxe der Migräne. Überarbeitete Empfehlungen der Deutschen Migräne- und Kopfschmerzgesellschaft. Münch. Med. Wschr. 134 (1992) 145-153
126. Steiner, T. J., R. Joseph, C. Hedman et al.: Metoprolol in the prophylaxis of migraine: parallel group comparison with placebo and dose-ranging follow-up. Headache 28 (1988) 15-23
127. Steinert, J., C. R. Pugh: Two patients with schizophrenic-like psychosis after treatment with beta-adrenergic blockers. Br. Med. J. 1 (1979) 790
128. Stellar, S., S. P. Ahrens, A. R. Meibohm et al.: Migraine prevention with timolol. J. Am. Med. Ass. 252 (1984) 2576-2579
129. Sudilovsky, A., A. H. Elkind, R. E. Ryan et al.: Comparative efficacy of nadolol and propranolol in the management of migraine. Headache 27 (1987) 421-426
130. Thiessen, B. Q., S. M. Wallace, J. L. Blackburg et al.: Increased prescribing of antidepressants subsequent to beta blocker therapy. Arch. Int. Med. 150 (1990) 2286-2290
131. Turki, J., J. Pak, S. A. Green. R. J. Martin, S. B. Ligett: Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly 16 correlates with the nocturnal phenotype. J. Clin. Invest. 95 (1995) 1635-1641
132. Tyrer, P.: Current status of β-blocking drugs in the treatment of anxiety disorders. Drugs 36 (1988) 773-783
133. van Zwieten, P. A., P. B. Timmermans: Comparison between the acute haemodynamic effects and brain penetration of atenolol and metoprolol. J. Cardiovasc. Pharmaco. 1 (1979) 85-89
134. Viadero, J. J., S. H. Wong, W. B. White: Acute psychotic behavior aassociated with atenolol. Am. J. Psychiatry 140 (1983) 1382
135. Waal, H. J.: Propranolol-induced depression Br. Med. J. II (1967) 50
136. Walston, J., K. Silver, C. Bogardus, W. C. Knowler, F. S. Celi, S. Austin, B. Manning, A. D. Strosberg, M. P. Stern, N. Raben, J. D. Sorkin, J. Roth, A. R. Shuldiner: Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the β3-adrenergic-receptor gene. N. Engl. J. Med. 333 (1995) 343-347
137. White, W. B., K. Riotte: Propranolol and white rabbits. N. Engl. J. Med. 307 (1982) 558-559
138. Whitlock, F. A., A. R. Bonfield: Propranolol psychosis. Med. J. Aust. I (1980) 184-185
139. Widen, E., M. Letho, T. Kaminen, J. Walston, A. R. Shuldiner, L. C. Groop: Association of a polymorphism in the β3-adrenergic receptor gene with features of the insulin resistance syndrome in finns. N. Engl. J. Med. 333 (1995) 348-351
140. Wilkie, T. M., Y. Chen, D. J. Gilbert et al.: Identification, chromosomal localization and genome organization of mammalian G-protein-coupled receptors. Genomics 18 (1993) 175-184
141. Winkler, G. F., R. R. Young: The control of essential tremor by propranolol. Trans. Am. Neurol. Assoc. 96 (1971) 66-68
142. Wörz, R., R. Reinhardt-Benmalek, M. Föh et al.: Migräneprophylaxe durch Bisoprolol. Fortschr. Med. 110 (1992) 268-272